124 related articles for article (PubMed ID: 9233651)
21. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
22. New insight into the role of phosphodiesterase 3A in porcine oocyte maturation.
Sasseville M; Côté N; Guillemette C; Richard FJ
BMC Dev Biol; 2006 Oct; 6():47. PubMed ID: 17038172
[TBL] [Abstract][Full Text] [Related]
23. A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis.
Hong J; Zang YC; Tejada-Simon MV; Kozovska M; Li S; Singh RA; Yang D; Rivera VM; Killian JK; Zhang JZ
J Immunol; 1999 Sep; 163(6):3530-8. PubMed ID: 10477628
[TBL] [Abstract][Full Text] [Related]
24. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
[TBL] [Abstract][Full Text] [Related]
25. Antagonists of cyclic nucleotide phosphodiesterase (PDE) isozymes PDE 3 and PDE 4 suppress lymphoblastic response to HLA class II alloantigens: a potential novel approach to preventing allograft rejection?
Dousa MK; Moore SB; Ploeger NA; DeGoey SR; Dousa TP
Clin Nephrol; 1997 Mar; 47(3):187-9. PubMed ID: 9105766
[TBL] [Abstract][Full Text] [Related]
26. A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells.
Ma R; Yang BY; Wu CY
Int Immunopharmacol; 2008 Oct; 8(10):1408-17. PubMed ID: 18687303
[TBL] [Abstract][Full Text] [Related]
27. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
[TBL] [Abstract][Full Text] [Related]
28. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
29. Characterization of 3',5' cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells: absence of functional PDE6.
White JB; Thompson WJ; Pittler SJ
Mol Vis; 2004 Oct; 10():738-49. PubMed ID: 15480303
[TBL] [Abstract][Full Text] [Related]
30. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation.
Thomas RE; Armstrong DT; Gilchrist RB
Dev Biol; 2002 Apr; 244(2):215-25. PubMed ID: 11944932
[TBL] [Abstract][Full Text] [Related]
31. Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99.
Ausubel LJ; Krieger JI; Hafler DA
J Immunol; 1997 Sep; 159(5):2502-12. PubMed ID: 9278344
[TBL] [Abstract][Full Text] [Related]
32. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
Rose RJ; Liu H; Palmer D; Maurice DH
Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
[TBL] [Abstract][Full Text] [Related]
33. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
34. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes.
Kerfant BG; Zhao D; Lorenzen-Schmidt I; Wilson LS; Cai S; Chen SR; Maurice DH; Backx PH
Circ Res; 2007 Aug; 101(4):400-8. PubMed ID: 17615371
[TBL] [Abstract][Full Text] [Related]
35. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
36. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
37. Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes.
Ekholm D; Mulloy JC; Gao G; Degerman E; Franchini G; Manganiello VC
Biochem Pharmacol; 1999 Sep; 58(6):935-50. PubMed ID: 10509746
[TBL] [Abstract][Full Text] [Related]
38. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells.
Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
Am J Respir Cell Mol Biol; 1995 Dec; 13(6):692-702. PubMed ID: 7576707
[TBL] [Abstract][Full Text] [Related]
39. Cyclic nucleotide phosphodiesterase 3B is a downstream target of protein kinase B and may be involved in regulation of effects of protein kinase B on thymidine incorporation in FDCP2 cells.
Ahmad F; Cong LN; Stenson Holst L; Wang LM; Rahn Landstrom T; Pierce JH; Quon MJ; Degerman E; Manganiello VC
J Immunol; 2000 May; 164(9):4678-88. PubMed ID: 10779773
[TBL] [Abstract][Full Text] [Related]
40. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D.
Wang P; Myers JG; Wu P; Cheewatrakoolpong B; Egan RW; Billah MM
Biochem Biophys Res Commun; 1997 May; 234(2):320-4. PubMed ID: 9177268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
